Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | TPO | P07202 | 1/20 | 0.34 |
| ▸ | EPX | P11678 | 1/20 | 0.34 |
| ▸ | LPO | P22079 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21630278 | 0.84 | MPO (0.33) | CHRNB2CHRNA4MPOTPOEPX | |
| SCHEMBL21630275 | 0.80 | GRM4 (0.36) | — | |
| SCHEMBL31296163 | 0.78 | CHRNA3 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL901182 | 0.77 | MAOA (0.47) | SCN9A | |
| SCHEMBL28564069 | 0.76 | GRM5 (0.36) | — | |
| SCHEMBL8126363 | 0.75 | LMNA (0.61) | — | |
| SCHEMBL21630305 | 0.74 | TEAD4 (0.44) | — | |
| SCHEMBL21630310 | 0.74 | MAPT (0.44) | — | |
| SCHEMBL28575004 | 0.74 | S1PR2 (0.34) | SCN9A | |
| SCHEMBL21630308 | 0.74 | SOS1 (0.38) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200029563-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYLDIOXOLANE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031778-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031778-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES | IPMK, PIP5K1B, PIP5K1C | CHRNB2 4870/4885CHRNB4 4818/4885CHRNA3 4787/4885 |
| US-20200029563-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYLDIOXOLANE DERIVATIVES | PIP5K1B, PIP5K1A, PIP5K1C | CHRNB2 4414/4885CHRNB4 4220/4885CHRNA3 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.